{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:38:23Z","timestamp":1762004303598},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Inher Metab Disea"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current treatment of mucopolysaccharidosis type II (MPS II, Hunter syndrome) is enzyme replacement therapy with recombinant idursulfase (Elaprase\u00ae). The efficacy of ERT was established based primarily on reduction in urine glycosaminoglycans:creatinine (GAG:Cr) ratio and improvement in a composite score of predicted forced vital capacity (FVC% predicted) and 6\u2010min walk\u2010test distance (6MWT). We retrospectively reviewed these parameters in 11 boys with MPS II treated with idursulfase between April 2007 (or the time of diagnosis) and February 2010. Some results were inconsistent with published trial data, and there was only a small number of analyzable results obtained for the FVC% predicted and 6MWT. A major drawback was the high prevalence of neurological involvement and young age of patients in the study cohort compared with the clinical trials. This study emphasizes the limitations of the current tools utilized to monitor ERT efficacy and MPS II disease burden in clinical practice.<\/jats:p>","DOI":"10.1007\/s10545-011-9280-1","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T17:22:02Z","timestamp":1297790522000},"page":"749-754","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points"],"prefix":"10.1002","volume":"34","author":[{"given":"Emma","family":"Glamuzina","sequence":"first","affiliation":[{"name":"Metabolic Department, 5th floor, Southwood Building Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Fettes","sequence":"additional","affiliation":[{"name":"Respiratory Physiology Department Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Bainbridge","sequence":"additional","affiliation":[{"name":"Enzyme Laboratory Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Crook","sequence":"additional","affiliation":[{"name":"Metabolic Department, 5th floor, Southwood Building Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Finnegan","sequence":"additional","affiliation":[{"name":"Metabolic Department, 5th floor, Southwood Building Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Abulhoul","sequence":"additional","affiliation":[{"name":"Metabolic Department, 5th floor, Southwood Building Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Vellodi","sequence":"additional","affiliation":[{"name":"Metabolic Department, 5th floor, Southwood Building Great Ormond Street Hospital for Children London WC1N 3JH United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.10.004"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.1998.2761"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.07.012"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","unstructured":"DavisonJ HendrikszC SunY DaviesN GissenP PeetA(2010)Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome).J Inherit Metab Dis[Epub ahead of print]","DOI":"10.1007\/s10545-010-9197-0"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2032"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0188-4409(00)00104-1"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2008.048512"},{"key":"e_1_2_5_10_1","unstructured":"International Conference on Harmonisation(1998)Harmonised tripartite guideline on statistical principles for clinical trials (E9) EMEA."},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20950"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.123653"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.03.015"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000232477.37660.fb"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.09.001"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.48.8.794"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","unstructured":"WoodM ClearyM AldersonL VellodiA(2009)Changes in gait pattern as assessed by the GAITRite walkway system in MPS II patients undergoing enzyme replacement therapy.J Inherit Metab Dis[Epub ahead of print]","DOI":"10.1007\/s10545-009-1103-2"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31817701e6"}],"container-title":["Journal of Inherited Metabolic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s10545-011-9280-1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1007\/s10545-011-9280-1","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s10545-011-9280-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:39:52Z","timestamp":1694810392000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/s10545-011-9280-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1007\/s10545-011-9280-1"],"URL":"https:\/\/doi.org\/10.1007\/s10545-011-9280-1","archive":["Portico"],"relation":{},"ISSN":["0141-8955","1573-2665"],"issn-type":[{"value":"0141-8955","type":"print"},{"value":"1573-2665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}